Sanofi Cons Healthc IND L
NSE: SANOFICONR · Pharmaceuticals · sector
₹3,249.70NSE close 2026-10-26
Key numbers
Market cap₹7,474 cr
Price₹3,249.70
52w high / low₹5,255 / ₹3,250
P/E28.1xSector median 27.9x
P/B21.5xSector median 2.9x
Book value₹151.3
Dividend yield–Sector median 0.48%
ROE88.0%Sector median 11.7%
ROCE103.2%Sector median 12.3%
OPM37.2%Sector median 14.0%
Debt / equity0.00xSector median 0.16x
EV/EBITDA19.8xSector median 18.6x
Interest cover179.6x
Current ratio2.03x
Sales growth 3y–Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG0.86x
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Operating profit covered interest 179.6x in the last 12 months.
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 7% of net profit in the last 12 months.
- Price ₹3,249.70 on 2026-10-26: -38.2% from the 52-week high, 0.0% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹5,421.00 · low ₹3,249.70
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 160 | 171 | 173 | 221 | 234 | 251 | 229 | 236 |
| EBITDA | 62 | 59 | 64 | 77 | 85 | 90 | 89 | 89 |
| OPM % | 38.7% | 34.7% | 37.1% | 34.8% | 36.3% | 35.8% | 38.7% | 37.9% |
| Other income | 4 | 5 | 5 | 6 | 3 | 5 | 6 | 6 |
| Net profit | 45 | 44 | 50 | 61 | 63 | 66 | 68 | 69 |
| EPS (₹) | 19.54 | 19.25 | 21.69 | 26.36 | 27.31 | 28.87 | 29.44 | 29.87 |
| Revenue YoY | +46.3% | +47.0% | +32.8% | +6.7% | ||||
| Profit YoY | +39.8% | +50.1% | +35.6% | +13.3% |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | TTM |
|---|---|
| Revenue | 950 |
| EBITDA | 353 |
| Net profit | 266 |
| EPS (₹) | 115.49 |
| Dividend / share (₹) |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | – | – | +31.2% |
| Net profit | – | – | +33.0% |
| EPS | – | – | – |
| Share price | – | -16.8% (2y) | -28.8% |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 71.27% |
| FIIs | 2.48% |
| DIIs | 18.03% |
| of which Mutual funds | 12.92% |
| of which Insurance | 5.11% |
| Government | 0.00% |
| Public (non-institutions) | 8.22% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 60.40% | 60.40% | 71.27% | 71.27% | 71.27% | 71.27% | 71.27% | 71.27% |
| Promoter group | % |
|---|---|
| Opella Healthcare Participations B.V. | 60.40% |
| Opal Bidco SAS | 10.88% |
| Hoechst GMBH | 0.00% |
| Sanofi | 0.00% |
| Opella Heathcare SAS, France | 0.00% |
| Winthrop Pharma Tunisie | 0.00% |
| OH Egypt LLC | 0.00% |
| OH Slovakia s.r.o | 0.00% |
| Sanofi Vietnam | 0.00% |
| Opella Canada Inc. | 0.00% |
| OH Gulf FZE | 0.00% |
| OH Korea Inc. | 0.00% |
| OH Philippines Inc. | 0.00% |
| SA healthcare pty Australia | 0.00% |
| OH Austria GmbH | 0.00% |
| Public holders above 1% | % |
|---|---|
| Nippon Life India Trustee Ltd- A/C Nippon India Growth MID CAP Fund | 5.96% |
| Aditya Birla SUN Life Mutual Fund - Aditya Birla SUN Life Consumption Fund | 2.94% |
| HDFC Life Insurance Company Limited | 2.33% |
| ICICI Prudential Smallcap Fund | 1.67% |
| General Insurance Corporation of India | 1.30% |
| Bajaj Life Insurance Limited | 1.09% |
46,586 shareholders. Pledged: – of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| SANOFICONR | ₹7,474 cr | 28.1x | 21.5x | 88.0% | 103.2% | 37.2% | – | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-06-19 | Dividend | Dividend - Rs 75 Per Share |
| 2025-04-17 | Dividend | Dividend - Rs 55 Per Share |
Documents
- Annual report FY25
- Annual report FY24
- Annual report FY24
- Announcements NSE filings
- BRSR FY25
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Manufacture and Sale of all pharmaceutical products: Drugs & Pharmaceutical
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | SANOFICONR |
| BSE code | 544250 |
| ISIN | INE0UOS01011 |
| Face value | ₹10.0 |
| Incorporated | 2023-05-10 |
| Website | https://www.sanofi.com/en/india |
| Plants (India / abroad) | 0 / 0 |
From the company's filings (BRSR FY25).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.